ESMO Inventory: Are you aware of these latest cancer advances?

Over the weekend, the latest clinical advances in a number of heavy-duty anticancer therapies were announced at the ESMO 2020 virtual conference, including Janssen's innovative dual-specific antibody therapy, Amgen's KRAS inhibitor, BMS's Opdivo immunological combination therapy, and Immunumdicomes' Trop-2 antibody-coupled drug Trodelvy.
today, the Pharmaceutical Mingkang content team will share with readers these latest clinical advances published at ESMO 2020.
treatment of EGFR mutation non-small cell lung cancer patients, Jansen double-specific antibody combination therapy achieved a 100% total remission rate Johnson and Johnson Janssen, a subsidiary of the Johnson Group, today announced the clinical results of stage 1b in patients with EGFR, MET dual-specific antibody amivantamab, in association with the third generation of EGFR tyrosine kinase inhibitor (TKI) lazertinib, to treat patients with non-small cell lung cancer with EGFR exon 19 loss or L858R mutations.
results showed that in 20 patients with NSCLC, the combination therapy achieved an objective remission rate (ORR) of 100%.
Amivamab, formerly known as JNJ-61186372, is a EGFR-MET dual-specific antibody with immune cell orientation activity, target activation and drug resistance EGFR mutations, as well as MET mutations and amplification.
it has been awarded a breakthrough treatment by the U.S. FDA to treat patients with NSCLC who carry EGFR exon 20 insertions.
Lazertinib is an oral third-generation EGFR TKI that can cross the cerebral blood barrier, targeting T790M mutations and activated EGFR mutations while protecting wild EGFR.
in an open-label, global multi-center study, 91 NSCLC patients with EGFR exon 19 deficiency or L858R mutations received a combined treatment of intravenous amantamab and oral lazertinib.
in the first treatment group, the ORR of 20 patients receiving co-treatment reached 100% (95% CI, 83-100) at a medium follow-up time of 7 months.
in 45 patients who relapsed after receiving osimertinib, the combined treatment of ORR reached 36% (95% CI, 22-51), including 1 complete remission and 15 partial remission.
based on this remarkable result, Jansen has initiated Phase 3 clinical trials to compare the efficacy of this combination therapy in patients with the first-line treatment of EGFR mutation NSCLC compared to the third generation of EGFR inhibitor osimertinib.
published the full results of KRAS G12C inhibitor sotorasib, non-small cell lung cancer disease control rate of 88.1% Amgen announced today, its KRAS G12C specific inhibitor sotorasib (formerly known as AMG510) in the full Phase 1 clinical results in the New England Journal of Medicine (NEJM).
results included 129 patients with solid tumors, 59 of whom were patients with advanced non-small cell lung cancer (NSCLC).
this data is also highlighted in the oral report of ESMO 2020.
test results showed that as of June 1 this year, sotorasib had an objective remission rate (ORR) and a disease control rate (DCR) of 34% of the 34 patients receiving a dose of 960 mg.
In patients with NSCLC, anti-cancer activity was found at all dose levels, with a confirmed ORR of 32.2%, DCR of 88.1%, a medium duration of 10.9 months, and 10 out of 19 patients who were relieved were still in remission at the data cut-off time.
patients treated with sotorasib had a median non-progression survival of 6.3 months.
, published in the New England Journal of Medicine, said Amiens' clinical trial results offer hope for targeting "non-drugable" KRAS targets.
follow-up combination therapy studies are expected to further improve the complete remission rate of KRAS G12C inhibition.
total lifetime is nearly doubled! A week before Trop-2 antibody-coupled drug Trodelvy significantly reduced the risk of death in patients with triple-negative breast cancer, Gilead Sciences said on a conference call that its $21 billion acquisition of Immunomedics had said that the company's antibody-coupled drug Trodelvy, which targets Trop-2, would be a cornerstone product of Gilead's research and development pipeline. Over the weekend, Immunomedics presented the results of a clinical trial of Trodelvy's treatment of patients with triple-negative breast cancer and metastatic urethra skin cancer at the ESMO 2020 Virtual Conference.
these excellent results are further evidence of Trodelvy's potential to treat multiple types of cancer.
in the ASCENT clinical trial for triple-negative breast cancer, patients with triple-negative breast cancer who participated in the clinical trial had received an average of four pre-cancer treatments.
results showed that the medium OS in patients treated with Trodelvy was 12.1 months, significantly better than the 6.7 months in the chemotherapy control group.
reduced the risk of death by 52% compared to the chemotherapy group (HR=0.48,95% CI, 0.38-0.59, p.lt;0.0001).
Trodelvy achieved 35% ORR at the same time, a statistically significant improvement over chemotherapy (5%).
same day, Immunomedics also released the results of a key Phase 2 clinical trial of Trodelvy in the treatment of metastatic urethra skin cancer patients (mUC).
Trodelvy achieved 31% ORR in these treated patients who had been treated with platinum-containing chemotherapy and immuno-checkpoint inhibitors, and the disease continued to progress, including 5% complete remission.
non-progressed lifetime reached 5.4 months and the mid-OS was 10.5 months.
"Considering that only 10 percent of mUC patients treated with platinum-containing chemotherapy and immuno-checkpoint inhibitors responded to subsequent single-drug chemotherapy with a medium progression-free survival of 2 to 3 months, today's dramatic results in sacituzumab govitecan offer new hope for patients and their families."
", said Dr Yohann Loriot, who reported the results on ESMO 2020.
patients with advanced renal cell carcinoma have doubled their progressed survival! The clinical results of Phase 3 clinical outcomes of TheOpdivo Combination Therapy of The hundred-time Mespresso (BMS) and Exelixis announced over the weekend the results of a critical Phase 3 clinical trial of the PD-1 inhibitor Opdivo (nivolumab) in combination with the tyrosine kinase inhibitor Cabozantinix ( cabozantinib) for the first-line treatment of advanced renal cell carcinoma (RCC).
results showed that this combination therapy reduced the risk of death by 40% compared to the active control group (HR=0.60, 98.89 CI:0.40,0.89, p=0.001).
progression survival (PFS) was 16.6 months for patients treated with combination therapy, twice as long as in the active control group (HR=0.51,95% CI:0.41,0.64, p<0.0001).
, the combined therapy had ANR of 56%, twice as high as that of the control group (27%).
all efficacy data were consistent among a variety of metastatic renal cell carcinoma sub-groups, including sub-groups of patients expressing different PD-L1 levels.
positive results, BMS and Exelixis have filed regulatory applications with regulators in the European Union and the United States.
resources: 1. Opdivo ® (nivolumab) in With CABOMETYX® (cabozantinib) Provs Great Benefit Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial. Retrieved September 19, 2020, from TAGRISSO Reduced the Risk of Disease Recurrence in the Brain by 82% in the Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer. Retrieved September 19, 2020, from Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothel Cancerial. Retrieved September 19, 2020, from TrodelvyTM Profile Extends In Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer. Retrieved September 19, 2020, from Clinical Data From Full Phase 1 Cohort Of Investigational Sotorasib Published In New England Journal Of Medicine. Retrieved September 20, 2020, from Janssen Presents Findings from Global, Multi-Center Trial Examining Amivantamab in Group with Lazertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer. Retrieved September 20, 2020, from . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .